Cambridge Healthtech Institute's Inaugural Targeting the Ubiquitin Pathway conference 2012

Drugs targeting the ubiquitin system are still relatively new; the first approval by the FDA happened in 2003. Ubiquitination (ligases) as well as deubiquitination (deubiquitylating enzymes (DUBs) play key roles in cellular signal transduction pathways and offer numerous opportunities for therapeutic interventions for treating diseases such as cancer, inflammation and metabolic diseases. However, in order to bring more ubiquitin targeting drugs to the market, some challenges need to be addressed and will be discussed at this meeting.

Cambridge Healthtech Institute's Inaugural Targeting the Ubiquitin Pathway conference is focused on drug discovery and development within the ubiquitin related pathway, such as ubiquitin pathway inhibitors, targeting ubiquitin ligases and learning from case studies. We are bringing together experts from the pharmaceutical industry, biotech and academia to exchange knowledge, discuss current challenges and interact in focused breakout discussions, poster sessions and network receptions.

Topics will include:
- Screening for Ubiquitin Ligase Inhibitors
- Targeting E2 - E3 Interactions
- Targeting Deubiquitinases
- Developing Chemical Libraries to Target DUBs
- Targeting E1, E2 or E3 Ligases
- Developing Small Molecule Inhibitors
- Ubiquitin-Like Modifiers in Signaling
- Targeting Conjugation/Deconjugation
- Targeting the Ubiquitin - Proteasome Pathway
- Bortezomib - Lessons Learned

Further details and to register